RxDoctor Payments Data

Govind Singh, MD

Family Medicine · Colfax, WANPI 1730199464

Payments from drug & device makers

$959in general payments, 2019–2025

Across 82 payments — averaging $11.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$142
  • Novo Nordisk$138
  • Amgen$128
  • Johnson & Johnson$94
  • GSK$70
  • Boehringer Ingelheim$51
  • plus $336 from 12 others

What the payments were for

  • Food & beverage$959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$959 in reported general payments places this provider in the 80th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$99,306
Medicare patients
277
Services billed
1,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$147,428
JardianceEmpagliflozin134$107,736
OzempicSemaglutide93$103,348
XareltoRivaroxaban99$74,020
FarxigaDapagliflozin Propanediol73$60,124
JanuviaSitagliptin Phosphate56$31,110
NuedextaDextromethorphan Hbr/Quinidine18$30,124
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$29,735
TrulicityDulaglutide18$26,109
EntrestoSacubitril/Valsartan20$21,343
RexultiBrexpiprazole15$20,595
MyrbetriqMirabegron41$19,857
Bydureon BciseExenatide Microspheres15$19,658
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$19,554
Breo ElliptaFluticasone/Vilanterol38$19,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$142$147,428210 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Glyxambi$51$127,951172 claims
Novo NordiskOzempic$138$103,34893 claims
Johnson & JohnsonXarelto$94$74,02099 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$70$68,682115 claims
MerckJanuvia$22$31,11056 claims
Lilly USA, LLCTrulicity$26$26,10918 claims
NovartisEntresto, Travatan Z$44$26,02039 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17$20,59515 claims
Astellas Pharma US IncMyrbetriq$37$19,85741 claims
AbbVieLinzess$41$9,10618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Colfax

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →